ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Down 25.3% in December

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 58,311 shares, a decrease of 25.3% from the December 15th total of 78,064 shares. Approximately 8.6% of the shares of the company are sold short. Based on an average trading volume of 18,189 shares, the days-to-cover ratio is presently 3.2 days. Based on an average trading volume of 18,189 shares, the days-to-cover ratio is presently 3.2 days. Approximately 8.6% of the shares of the company are sold short.

ENDRA Life Sciences Price Performance

Shares of NDRA stock traded up $0.31 during midday trading on Friday, reaching $4.78. 11,041 shares of the company traded hands, compared to its average volume of 14,628. The firm has a market cap of $3.59 million, a PE ratio of -0.18 and a beta of -0.31. ENDRA Life Sciences has a 1-year low of $2.90 and a 1-year high of $11.96. The firm’s 50 day simple moving average is $5.32 and its two-hundred day simple moving average is $5.37.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings results on Friday, November 14th. The company reported ($1.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.95) by $0.20. As a group, research analysts anticipate that ENDRA Life Sciences will post -47.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of ENDRA Life Sciences to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Wednesday, October 8th. Finally, Ascendiant Capital Markets lowered their target price on shares of ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, December 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.